Price To Earnings Ratio 70.18 | Sector PE 65.63 |
PB Ratio 13.96 | Sector PB 8.94 |
EPS 42.85 | Dividend Yield 1.06 |
Today's Volume 46.068 K | 5 Day Avg. Volume 119.013 K |
PEG Ratio 1.42 | Market Cap. ₹ 24,630.00 Cr. |
Time | LALPATHLAB | VS | Industry |
---|---|---|---|
1 Day | 0.72% | 1.74% | |
1 Week | 3.39% | 4.47% | |
1 Month | -7.78% | 9.12% | |
6 Months | 15.21% | 18.48% | |
1 Year | 9.15% | 42.12% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 3017.44 | Bearish |
20 | 3050.15 | Bearish |
30 | 3157.01 | Bearish |
50 | 3242.55 | Bearish |
100 | 3197.72 | Bearish |
200 | 2811.86 | Bullish |
Annual | FY 2024 | FY 2023 | FY 2022 | ||||
---|---|---|---|---|---|---|---|
Operating Activities | 535.33 | 456.03 | 446.69 | ||||
Investing Activities | -24.27 | -287.31 | -449.25 | ||||
Financing Activities | -413.86 | -283.18 | 136.45 | ||||
Net Cash Flow | 97.20 | -114.46 | 133.90 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
Dr. Lal Path Labs | 0.72 | 3.39 | -7.78 | 15.21 | 9.15 |
Aarti Drugs | -2.11 | -4.16 | -7.78 | -3.52 | 1.84 |
Abbott India | 2.27 | 0.68 | -3.61 | 3.38 | 20.65 |
Advanced Enzyme Tech | -1.75 | -2.83 | -16.09 | -7.13 | 13.28 |
Ajanta Pharmaceuticals | 0.73 | 5.25 | 1.62 | 13.32 | 47.04 |
Dr. Lal PathLabs Limited is an Indian company providing diagnostic and related healthcare tests and services. The company's activities include management of biochemistry, haematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology and other pathological and radiological research laboratories. It offers a variety of condition-based tests, including allergies, diabetes, health checks, viral infections, fever, heart disease, hypertension, cancer, miscarriages, anaemia, arthritis, breast cancer, diphtheria, liver disease, bone disease, abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscle disorders and viral infections. The company's subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited and Dr. Lal PathLabs Nepal Private Limited.